Hematologic Oncology

Bijal Shah, MD, MS, and Jae Park, MD, discuss how inotuzumab exposure may influence response to obe-cel in ALL.

Bijal Shah, MD, MS, and Jae Park, MD, predictors of sustained remission with obe-cel in acute lymphoblastic leukemia.

Shahzad Raza, MD, shares preliminary data from the NEXICART-2 trial of NXC-201 in relapsed/refractory light chain amyloidosis.

Here is your guide to all therapeutic options that were cleared by the FDA in June 2025 spanning tumor types.

Experts in the fields of lung, head and neck, HER2+ breast, and hematologic cancers discuss notable updates for fellows from the 2025 AACR Annual Meeting.

Ajai Chari, MD, highlighted key areas of debate in smoldering myeloma from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

OncLive® showcases 13 cancer care pioneers, who have won the 2025 Giants of Cancer Care award.

The FDA grants approval to Dato-DXd in EGFR+ NSCLC, revumenib sNDA is under priority review for NPM1-mutant AML, and more from OncLive this week.

The FDA updated the labels for liso-cel and ide-cel to reduce monitoring select requirements and remove REMS programs for the CAR T-cell therapies.

Alexey Danilov, MD, PhD, highlights the importance of re-evaluating sequencing strategies amid a growing arsenal of targeted therapies in DLBCL.

The EMA’s CHMP has recommended the approval of zanubrutinib tablets for B-cell malignancies.

Andrew Kuykendall, MD, discusses the utility of rusfertide in reducing therapeutic phlebotomy eligibility in patients with polycythemia vera.

Revumenib’s sNDA has received priority review from the FDA for patients with relapsed or refractory NPM1-mutant acute myeloid leukemia.

Bijal Shah, MD, MS, and Jae Park, MD, discuss an age-based analysis of outcomes with obe-cel in acute lymphoblastic leukemia.

Bijal Shah, MD, MS, and Jae Park, MD, discuss how the integration of obe-cel has affected the acute lymphoblastic treatment paradigm.

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, on the current management of paroxysmal nocturnal hemoglobinuria.

The top 5 OncLive videos of the week cover insights in CLL, multiple myeloma, follicular lymphoma, and extrapulmonary neuroendocrine carcinomas.

Tafasitamab combination gets approval in follicular lymphoma, FDA declines to expand label for talazoparib plus enzalutamide in mCRPC, and more.

The EMA’s CHMP has issued a positive opinion for UM171 cell therapy for patients with hematological malignancies and limited stem cell transplant options.

Manali Kamdar, MD, discusses evolving treatment paradigms in diffuse large B-cell lymphoma.

BGB-16673 was safe and effective for the treatment of patients with relapsed/refractory Waldenström Macroglobulinemia.

Galleri, a multicancer early detection test, demonstrated high positive predictive value and cancer detection in PATHFINDER 2.

SENTI-202 receives FDA orphan drug designation for treating relapsed/refractory hematologic malignancies, including AML.

Hematologic oncology experts share the studies they were most excited to see presented at the 2025 EHA Congress.

Bexobrutideg was safe and displayed an ORR of 84.2% in relapsed/refractory Waldenström macroglobulinemia.